No Image Provided

Antidote Technologies

VC Funding

Series A

Healthcare & Biotech Published 22 August 2017

Summary

In a significant market movement during August 2017, Antidote Technologies was the subject of a vc funding. The transaction achieved a gross valuation of £8,577,867. Leading the round was Merck Global Health Innovation Fund.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Merck Global Health Innovation Fund

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series A prioritised

VC Funding

Newcells Biotech

£2,350,000

Feb 2024

VC Funding

HutanBio

£2,250,000

Jan 2024

VC Funding

Lottie

£17,253,062

Oct 2023

VC Funding

Skin Analytics

£4,000,000

Sept 2020

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.